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In Brief WHIM syndrome is an inherited immunodeficiency caused by overactivity of CXCR4, a receptor controlling production and distribution of leukocytes in bone marrow and blood. We identified a WHIM patient cured by chromothripsis (chromosome shattering) that fortuitously deleted the abnormal copy of the CXCR4 gene in a single hematopoietic stem cell, which then took over the bone marrow and restored normal immune function. This experiment of nature suggests that partial CXCR4 inactivation might enhance engraftment of bone marrow in patients requiring transplantation. McDermott et al., 2015 , Cell 160, 686-699 February 12, 2015 ª2015 Elsevier Inc. http://dx.doi.org/10.1016/j.cell.2015.01.014
INTRODUCTION
WHIM syndrome is an autosomal dominant combined primary immunodeficiency disease caused by mutations in the chemokine receptor CXCR4 (Hernandez et al., 2003) . The term ''WHIM'' is an acronym for the main manifestations of the disease: warts, hypogammaglobulinemia, recurrent infections, and myelokathexis; myelokathexis refers to impaired egress of mature neutrophils from bone marrow causing neutropenia (Wetzler et al., 1990; Zuelzer, 1964) . Most patients with WHIM syndrome are actually panleukopenic, with severely reduced peripheral blood B cells but less severe reductions in peripheral blood T cells and monocytes (McDermott et al., 2011) . The signature pathogen in WHIM syndrome is human papillomavirus (HPV), which causes warts that cannot be controlled with standard medical treatment and may progress to cancer (Al Ustwani et al., 2014; Beaussant Cohen et al., 2012; Dotta et al., 2011; Kawai and Malech, 2009) . Recurrent bacterial infections also occur, mainly in the sinopulmonary tract, oral cavity, ear, skin, and soft tissue, where chronic complications may arise, especially bronchiectasis and hearing loss. Prophylactic antibiotics, IVIg and G-CSF are often used to reduce the incidence of infections; however, their precise efficacy has not been established (Al Ustwani et al., 2014; Beaussant Cohen et al., 2012; Dotta et al., 2011; Kawai and Malech, 2009 ). In contrast, safety and preliminary evidence of clinical efficacy has recently been reported from Phase I studies of the specific CXCR4 antagonist plerixafor (Mozobil, AMD3100) (Dale et al., 2011; McDermott et al., 2011 McDermott et al., , 2014 . Spontaneous remission or cure of WHIM syndrome has not been previously reported.
WHIM mutations of CXCR4 increase signaling because they disrupt negative regulatory elements in the carboxy-terminus, thereby exaggerating the normal hematopoietic functions of the receptor (Haribabu et al., 1997; Signoret et al., 1998; Venkatesan et al., 2003) . CXCR4 is normally expressed by most leukocytes and has one ligand, CXCL12 (Bachelerie et al., 2014; Bleul et al., 1996) , which is constitutively expressed at high levels by stromal cells in the bone marrow and normally mediates HSC retention in bone marrow niches (Broxmeyer et al., 2003b; Broxmeyer et al., 2005; Dar et al., 2006; Sugiyama et al., 2006; Zou et al., 1998) . In addition, CXCR4 signaling promotes hematopoietic stem cell (HSC) quiescence, homing to bone marrow from blood and differentiation into committed myeloid progenitors (Broxmeyer et al., 2003a (Broxmeyer et al., , 2003b Kawai et al., 2007; Nie et al., 2008; Sugiyama et al., 2006) .
Chromothripsis refers to multiple clustered genetic rearrangements and deletions affecting one or a few chromosomes (Stephens et al., 2011) . The abnormalities are thought to occur all at once in a single cell, which then presumably either dies or acquires a growth advantage, depending on the genes affected (Stephens et al., 2011) . Accordingly, chromothripsis was first identified by whole genome sequencing of cancer cell lines and has been reported to affect $2% of all cancers (Jones and Jallepalli, 2012) , as well as one patient with a severe congenital cognitive syndrome (Kloosterman et al., 2011) . Criteria for chromothripsis include (1) clustering of breakpoints in limited areas of one or several chromosomes with large intervening regions of normal sequence, (2) copy number states that suddenly oscillate between areas of normal heterozygosity and loss of heterozygosity, and (3) rearrangements affecting a single haplotype with multiple fragments rearranged in random orientation and order (Korbel and Campbell, 2013) . Here, we describe chromothriptic deletions of one copy of chromosome 2, including deletion of the disease allele CXCR4
R334X
, in a patient with WHIM syndrome that resulted in cure of the disease.
RESULTS

Cure of a Patient with WHIM Syndrome
The index patient, designated WHIM-09, is a white female who presented at age 58 to the NIH requesting evaluation for herself and two of her three daughters, designated WHIM-10 (age 21) and WHIM-11 (age 23) ( Figure 1A ). Both daughters had a history of recurrent infections since early childhood, multiple cutaneous warts, panleukopenia, and hypogammaglobulinemia, and therefore fulfilled all the clinical criteria for WHIM syndrome. In contrast, WHIM-09 reported that from childhood through age 38 she had had many serious infections, often requiring hospitalization, but then none in the 20 subsequent years, and that she had had confluent warts on her hands that spontaneously resolved also in her 30s ( Figure 1B) . Moreover, we found that at the time of presentation, WHIM-09 was not neutropenic, but instead had a mild leukocytosis, including an absolute neutrophil count (ANC) and absolute monocyte count (AMC) that were $2-fold greater than the upper limit of normal; in contrast, the absolute lymphocyte count (ALC) was within normal limits. The past medical history revealed that WHIM-09 was in fact the first patient ever described with myelokathexis, the key hematopathologic feature in WHIM syndrome, reported in two articles published in The New England Journal of Medicine (NEJM) in 1964 (Krill et al., 1964; Zuelzer, 1964) . She underwent a therapeutic splenectomy at age 9 for the possibility of autoimmune neutropenia, which was ineffective. There is no evidence that her parents or siblings had WHIM syndrome. Thus, the history and clinical evidence were compatible with a WHIM mutation occurring de novo in patient WHIM-09, autosomal dominant transmission to two of her three daughters, and spontaneous and durable complete clinical remission in WHIM-09 in her fourth decade of life ( Figure 1A ).
To evaluate potential mechanisms for clinical remission, we first graphed all available white blood cell counts for WHIM-09, including those previously published in the NEJM ( Figure 1C) . Consistent with the clinical history, this revealed severe neutropenia at least from age 9 that was unaffected by splenectomy but that began to resolve spontaneously early in the fourth decade of life, rising slowly over time to a new and stable baseline slightly above the upper limit of normal. The AMC followed the same time course, whereas, interestingly, the ALC did not, starting in the normal range for healthy individuals as a child then increasing inconsistently and only slightly as an adult. Nevertheless, when lymphocyte subsets were examined in detail, all B cell subsets and both naive CD4 + and CD8 + T cell subsets were below the lower limit of normal (Table 1) , as they were in both daughters and most other patients reported with WHIM syndrome. Consistent with this, WHIM-09 was slightly hypogammaglobulinemic at the time of presentation to NIH with IgG = 535 mg/dl (normal range, 642-1,730 mg/dl). In contrast, memory CD4 + and CD8 + T cell subsets were elevated in WHIM-09, but deficient in both daughters. Unfortunately, WHIM-09's archival lymphocyte subset values from the years when she fulfilled the clinical criteria for WHIM syndrome were not available. We considered myeloid leukemia or a possible pre-leukemic state as a cause of her mild leukocytosis; however, the patient was clinically well over this $20-year time span when her neutrophils and monocytes were increasing, and her blood smear and bone marrow histopathology at the NIH were not consistent with these diagnoses ( Figure 1D) ; moreover, specific testing for B and T cell clonality as well as for BCR-ABL and JAK mutations were negative (see Extended Experimental Procedures for details). Consistent with her apparent $20-year complete remission of WHIM syndrome by clinical criteria, her bone marrow did not present the characteristic features of the disease (increased myeloid:erythroid ratio, neutrophil vacuolization, eyeglass nuclei in neutrophils), which were, however, all present in her bone marrow histopathology reported in the NEJM in 1964, shown again here for comparison, with permission, in Figure 1D (Zuelzer, 1964) . Since the patient reported she had undergone several prior surgeries and blood transfusions, we tested her blood for evidence of allogeneic chimerism and found none (data not shown). Thus, although the patient appeared to be clinically cured, she was hematologically mosaic, with sustained spontaneous correction of neutropenia, monocytopenia, and myelokathexis, and continued deficiency of B and naive T lymphocytes in the blood.
Patient WHIM-09 Is a Genetic Mosaic for CXCR4 R334X , the Most Common Mutation Causing WHIM Syndrome We next genotyped whole blood DNA from family members using an established PCR-BstUI restriction fragment length polymorphism (PCR-RFLP) assay for the most common mutation in WHIM syndrome, CXCR4 R334X . Both affected daughters (WHIM-10 and WHIM-11) tested positive, whereas the unaffected husband and third unaffected daughter tested negative. Surprisingly, two independent whole blood samples from WHIM-09, in which the leukocyte content was composed mostly of neutrophils and monocytes ( Figures 1E and 1F ), also tested negative for the mutation. In contrast, DNA from WHIM-09 PBMCs, which were composed mostly of lymphocytes, as well as from a lymphoblastoid cell line generated from WHIM-09 PBMCs both tested positive for CXCR4 R334X ( Figure 1E ). The mutation was also not detectable by direct sequencing of whole blood cell DNA from WHIM-09, whereas whole blood cell samples from both daughters, WHIM-10 and WHIM-11, were both positive ( Figure 1F ). In contrast, DNA samples from a cheek swab and fibroblasts cultured from a skin biopsy from WHIM-09 were both heterozygous for CXCR4 R334X (Figures 1E and 1G) , defining her as a somatic genetic mosaic. A WHIM pedigree with germ-line/somatic genetic mosaicism, where the mother of two affected children was hematologically normal, has previously been described (Hernandez et al., 2003) , but was unlikely to apply to WHIM-09 since she had been markedly symptomatic with severe neutropenia and myelokathexis as a child and cutaneous warts as an adult (Krill et al., 1964; Zuelzer, 1964) . Therefore, we investigated whether a genetic reversion had occurred.
Chromothripsis as the Mechanism for Genetic Mosaicism in Patient WHIM-09
The PCR-RFLP assay and DNA sequencing results may both be explained by either reversion or deletion in patient leukocytes of the mutant nucleotide that defines the CXCR4 R334X allele. To address this, we first performed cytogenetic analysis of bone marrow cells. In all 20 metaphase cells examined, one copy of chromosome 2, where CXCR4 is located, was acrocentric rather than submetacentric and was significantly shorter than its normal homolog ( Figure 2A ). All other chromosomes appeared normal. In addition to deletions, the banding pattern of the abnormal chromosome 2 suggested the presence of inversions. Fluorescence in situ hybridization (FISH) revealed that the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, at 2p23 on the normal chromosome 2, was on the long arm of the abnormal chromosome 2 ( Figure 2B ). FISH also demonstrated that the abnormal chromosome 2 had a portion of the centromere inverted into the long arm and the N-myc gene (MYCN), normally on 2p24, was absent ( Figure 2C ). Almost all of the interphase bone marrow cells with polymorphic nuclei, consistent with neutrophils, had the abnormal hybridization patterns of the abnormal chromosome 2 ( Figure 2C ), whereas cells with round nuclei had a significantly lower percentage of the abnormal chromosome (data not shown). An immunohistochemical stain of ALK activity on a bone marrow core biopsy section did not reveal abnormal activation of the enzyme despite its abnormal chromosomal location ( Figure S1 ).
To define the chromosomal abnormalities with greater resolution, microarray was performed using patient bone marrow cell and cultured fibroblast DNA. This revealed that the abnormal chromosome 2 was $35 Mb shorter than usual due to seven large deletions ( Figure S2A ), as demonstrated by loss of heterozygosity in these regions and by an abrupt change in the relative copy number from 2 to 1. One of the deletions involved the MYCN gene, confirming the FISH results. In addition, one of the deletions included the position of the CXCR4 gene ( Figure S2B ). This had made the patient hemizygous for CXCR4 in cells having the abnormal chromosome 2 with loss of the CXCR4 R334X mutation as well as loss of one copy of 163 other annotated genes (Table S1 ). Thus, development of hemizygosity of CXCR4, with only the wild-type copy remaining, explained why the CXCR4 R334X mutation was not detectable in neutrophil DNA by either DNA sequencing or PCR-RFLP. However, this potentially fortuitous deletion was clearly only a small part of a much larger and more complex genetic event.
We next performed whole genome sequencing (WGS) for single nucleotide definition of the event, comparing blood neutrophil and skin fibroblast DNA from WHIM-09 to each other and to the standard human genome sequence in GenBank (version hg19). We obtained an average of 403 coverage of both samples (database of Genotypes and Phenotypes [dbGaP] accession number phs000856.v1.p1.
[http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi? study_id=phs000856.v1.p1]) and an analysis was performed to locate the DNA reads that had homology with multiple distinct areas of chromosome 2. This technique allowed precise base pair level identification of the inversions and deletions that had occurred on one copy of chromosome 2 (Table S2) . No other large deletions or inversions were detected in the genome.
The changes seen in the microarray were confirmed by WGS but were actually more complex than had been initially suspected. The derivative chromosome was composed of 18 remaining pieces arranged in random orientation and in a random order, characteristic of chromothripsis ( Figure 3A) . A circular plot of the connections revealed by paired end WGS of the neutrophil DNA is shown in Figure 3B . The abnormal derivative chromosome, modeled using the breakpoints and connections ( Figure 3C ), revealed a predicted structural banding pattern that was identical to what was observed by cytogenetic analysis. We also developed primer pairs spanning four (D) Normalization of bone marrow pathology in patient WHIM-09. A representative high magnification (5003) Wright-Giemsa stain of the bone marrow aspirate is shown for the index patient WHIM-09 in 1963 (Zuelzer, 1964) (reproduced with permission) and in 2013 at ages 9 and 59, respectively. Arrows in left image, eyeglass nuclei in neutrophils. (E) PCR-BstUI restriction fragment length polymorphism (BstUI) analysis of genomic DNA. HD, healthy donor; WHIM-09, index patient; Cheek, cheek swab cells; PBMC, peripheral blood mononuclear cells; Fb, fibroblast; LCL, lymphoblastoid cell line; WB, whole blood; WT, wild-type allele; WHIM, CXCR4 R334X allele that causes WHIM syndrome. (F) Sanger DNA sequencing analysis of whole blood DNA for affected family members in the region near nucleotide position 1,000 (vertical line), the site of WHIM mutation CXCR4 R334X (1,000 C / T). Blue, C; Red, T; Fb, fibroblast; PMN, polymorphonuclear leukocyte (PMN).
(G) Sanger DNA sequencing analysis of DNA from purified peripheral blood neutrophils, cells obtained from a buccal swab (cheek) and cultured skin fibroblasts for patient WHIM-09 in the same region as (F).
of the unique chromothriptic boundaries and demonstrated experimentally that they generated the predicted rearranged product from WHIM-09 neutrophil DNA but not from healthy donor DNA (data not shown). By analyzing the rearrangement breakpoints for the creation of novel fusion genes, we found two possibilities, fusions of MFSD2B with LOC285000 and POTEKP with NCKAP5 ( Figure S3) ; however, these genes are unlikely to be expressed or functional because each lacks a promoter and transcription initiation site, and major regions of the potentially fused genes are deleted. Thus, the most likely explanation for the patient's clinical improvement was haploinsufficiency for one or more of the 164 genes affected by chromothripsis.
Myeloid/Lymphoid Mosaicism Established by Chromothripsis in an HSC from Patient WHIM-09
Chromothripsis-specific primers did not generate a detectable product by PCR when DNA prepared from the archival spleen sample from patient WHIM-09 was amplified, suggesting that the chromothriptic event occurred after age 9, when splenectomy was performed, but before age 35, when the rise in WBC was already underway ( Figure 4A ). Figure 4D , lower panel). This pattern was confirmed by PCR using chromothripsis-specific primers and DNA from HSCs, CMPs, and CLPs ( Figure 4D , upper panel). Consistent with this, we found that all mature myeloid cell types tested in both blood and bone marrow lacked or were markedly deficient in the CXCR4 R334X WHIM allele, whereas all mature lymphoid cell types tested in peripheral blood and bone marrow were heterozygous CXCR4 +/R334X ( Figures 4B and 4C ). This aligns with the cytogenetic results presented in Figure 2C . Further, we found 100% of EBV-transformed B cell lines (n = 10) prepared from patient blood lacked the chromothriptic chromosome (data not shown). As expected, erythroid precursors, which derive from CMPs, also lacked the CXCR4 R334X allele as demonstrated by BstUI PCR-RFLP analysis of Burst Forming Unit-Erythroid (BFU-E) colonies generated from patient CD34 + cells cultured from PBMCs ex vivo ( Figure 4E ).
Thus, the combined evidence suggests that an HSC underwent chromothripsis and selectively repopulated the myeloid lineage (including the erythroid lineage), but not the lymphoid lineage ( Figure 4F ). Purified neutrophil and cultured skin fibroblast DNA from patient WHIM-09 was isolated and subjected to whole genome sequencing with paired-end analysis.
(A) Linear non-proportional plot of the abnormal copy of chromosome 2 in patient WHIM-09 labeled from the p arm telomere (0) to the q arm telomere (243) in megabases with the 18 remaining pieces arranged in their numeric order (top). Connections between these pieces are depicted by the curved lines. Note that some connections were poorly defined because of the involvement of repetitive centromeric sequence (black lines). The order and orientation of the 18 remaining pieces in the derivative chromosome are indicated at the bottom. (B) Circos plot of chromosome 2 and its normal Giemsa cytogenetic banding pattern labeled from the p arm telomere (0) to the q arm telomere ($240) in megabases. Large pieces of chromosome 2 were missing from patient WHIM-09 neutrophil DNA and the 18 remaining pieces were arranged in random order. Connections between these pieces and their orientation (inset) are depicted by the colored lines. See Figure S2 and Tables S1 and S2 for additional details. Note that two connections were poorly defined because of the involvement of repetitive centromeric sequence. The inner circular trace is the copy number variation data derived from microarray analysis ( Figures S2A and S2B) . Note that the sites of connections derived from the paired-end sequencing analysis closely match the sites where copy number variation abruptly falls from 2 to 1. The location of CXCR4 is indicated at lower left. leukocyte subsets had increased to $95% ( Figure 5A) . The rate at which the proportion of donor-derived blood cells diverged in frequency from the input ratio of 50:50 occurred in two phases, a rapid early phase within 2 weeks and a slow late phase evident by 2 weeks after transplantation. The inflection point could be earlier than 2 weeks, since this is the first time point when data were collected to allow for recovery after transplantation. Importantly, there was no difference in the baseline HSC frequency in bone marrow for Cxcr4 (A-E) Representative results from a BstUI PCR-restriction fragment length polymorphism assay (BstUI), designed to distinguish the wild-type CXCR4 allele (WT) from the CXCR4 R334X WHIM allele (WHIM), as well as from a PCR assay specific for the chromothriptic chromosome (13-16 Jxn). PCR was performed on DNA obtained from the indicated donor leukocyte subsets purified either from blood using magnetic bead purification (B and E) or from a bone marrow aspirate using flow cytometric sorting (C and D). DNA was also prepared from archived WHIM-09 spleen and compared with peripheral blood PMN DNA (A), as well as from Burst-forming Unit-Erythroid colonies and compared with blood leukocyte subsets (E ; green, positive for CXCR4 R334X ; asterisks, purified cell types directly analyzed by PCR-RFLP for the WHIM mutation. See also Figure S4 .
and Cxcr4 +/S338X donor mice, so the number of HSCs transplanted was similar ( Figure S5 ). Since the ANC in the peripheral blood of Cxcr4 +/S338X donor mice is only $50% Figure S5 ). In this case, the input ratio was skewed slightly in favor of the Cxcr4 +/+ cells over the Cxcr4 +/o cells (58%:42%). Nevertheless, by day 303 post-transplantation, when the animals were sacrificed, the percentage of Cxcr4 +/+ neutrophils, monocytes and B cells detectable in the peripheral blood had declined to less than $15%, whereas the percentage of each of the corresponding Cxcr4 +/o leukocyte subsets had increased to $85% with similar kinetics as for the competition with Cxcr4 +/S338X bone marrow ( Figure 5B ). The same effect was observed whether the irradiated recipient mouse was CD45.1, CD45.2, or Cxcr4
(data not shown) and whether the donor bone marrows were depleted of lineage-positive cells ( Figure S6 ).
To investigate the mechanism for the apparent competitive advantage of Cxcr4 +/o over Cxcr4 +/+ bone marrow cells for reconstituting the blood, we first measured the proliferative status of the corresponding HSCs in vivo by BrdU incorporation early after transplantation (day 7) ( Figure 6A Figure 6B ). Finally, when Cxcr4 +/o bone marrow was used in competitive repopulation assays with either Cxcr4 +/+ or Cxcr4 +/S338X , we found in both cases that the total white blood cell and differential counts in the blood post-transplantation were not significantly altered as compared to reference values for C57Bl/6J mice (http://phenome.jax.org), suggesting that Cxcr4 +/o genotype does not predispose to myelodysplasia or leukemia in the setting of this transplantation model (Figure S7) . Moreover, there is no evidence that Cxcr4 +/o mice have a constitutive predisposition to myelodysplasia (data not shown).
DISCUSSION
Our analysis of this unprecedented experiment of nature in a single patient provides the first evidence that chromothripsis, a newly described form of genetic instability, may result in clinical benefit, in particular, cure of an inherited disease. This patient also provides the second example of chromothripsis occurring in a stem cell still capable of terminal differentiation, (Kloosterman et al., 2011) as well as one of the few examples of spontaneous genetic cure of a Mendelian condition (Hirschhorn, 2003) . We use the word ''cure'' to refer to the patient's clinical outcome because she had met all four of the acronymic clinical criteria diagnostic for WHIM syndrome through her fourth decade of life, but has fulfilled none except for mild hypogammaglobulinemia since then ($20 years, to date). Moreover, the disease allele CXCR4 R334X is no longer detectable in key cell types that drive the disease: HSCs, neutrophils, and monocytes. To our knowledge, patient WHIM-09's spontaneous long-term complete remission of warts without treatment is unprecedented in WHIM syndrome (Al Ustwani et al., 2014; Beaussant Cohen et al., 2012; Kawai and Malech, 2009; Tassone et al., 2009; Wetzler et al., 1990) . Since she remains lymphopenic (B and naive T lymphocytes), this suggests that the myeloid arm of the immune system, probably through monocytes or monocyte-derived cells, plays an essential role in HPV clearance.
The combined evidence suggests that an HSC in WHIM-09 underwent chromothripsis between the second and fourth decade of life and selectively repopulated the myeloid lineage, but not the lymphoid lineage. This pattern of hematologic mosaicism implies that the chromothriptic changes precluded differentiation of HSCs to CLPs but not to CMPs. Thus, the mechanism for maintenance of the B cell lineage, which is WHIM in the patient, is unclear. Possibilities include differentiation from a small population of persistent WHIM HSCs below the level of detection of our assays, or by differentiation of self-sustaining or very long-lived WHIM CLPs. In contrast, the T cell lineage may simply have been maintained by homeostatic proliferation of the pre-chromothriptic WHIM T cell repertoire.
Chromothripsis is a complex chromosomal catastrophe that is thought to occur all at once in one cell (Stephens et al., 2011) . If the affected cell dies, chromothripsis is clinically silent and undetectable, therefore the true frequency with which it occurs cannot be determined. If the chromothriptic cell acquires a strong selective advantage, it may emerge as a readily detectable, clinically apparent clonal population harboring a single (Challen et al., 2012) , MYCN (Laurenti et al., 2008) , and IL1R (Orelio et al., 2009) , have been reported to regulate hematopoiesis (Table S1 ). That Cxcr4 haploinsufficiency should provide a competitive engraftment advantage to HSCs is somewhat counterintuitive since Cxcr4 has been well-documented to promote HSC homing to and retention in bone marrow (Broxmeyer et al., 2003a (Broxmeyer et al., , 2003b (Broxmeyer et al., , 2005 Dar et al., 2006; Kawai et al., 2007; Nie et al., 2008; Sugiyama et al., 2006) . However, it has also been reported that CXCL12 secreted by CXCL12-abundant reticular (CAR) cells that contact HSCs in the bone marrow niche is able to enhance HSC quiescence by stimulating CXCR4 signaling (Nie et al., 2008; Sugiyama et al., 2006) . The overall effect on engraftment of reducing signaling via CXCR4 haploinsufficiency has not been previously tested in vivo and cannot be confidently predicted given the diverse and contrasting roles of the receptor on HSCs as well as on mature leukocytes. Our mouse data confirmed in vivo that Cxcr4 haploinsufficiency enhanced HSC proliferation while maintaining longterm hematopoiesis, therefore a competitive advantage acquired from enhanced proliferation and potentially other mechanisms by these cells may supercede any potential disadvantage they may have at the level of bone marrow retention and homing.
Additional work using more stringent engraftment protocols in mice and ultimately gene editing/transplantation trials in humans will be needed to precisely determine the impact of CXCR4 haploinsufficiency on HSC engraftment as well as on each of the parameters that regulate the physiologic steady-state levels of mature leukocytes and hematopoietic stem and progenitor cells in blood, bone marrow, and other hematopoietic compartments. Such studies may further elucidate precisely how patient WHIM-09 was cured, which may point to general applications in transplantation and gene therapy.
EXPERIMENTAL PROCEDURES Patients
Consistent with the Declaration of Helsinki, all human subjects signed informed consent to participate in NIAID Institutional Review Board-approved clinical protocols. All subjects were studied at the NIH Clinical Center.
Human Leukocyte Analysis
Leukocyte subsets were isolated from blood and bone marrow. PBMCs and bone marrow cells were cultured ex vivo to expand CD34 + hematopoietic progenitor cells and to generate BFU-E colonies. PBMCs were used to create lymphoblastoid cell lines (LCL) from Epstein-Barr virus (EBV)-transformed B cells.
Genetic Analysis
BstUI PCR-RFLP analysis was performed as previously described (Hernandez et al., 2003) using patient genomic DNA. The genome was also analyzed by PCR using primers spanning chromothriptic junctions of the derivative chromosome 2 of patient WHIM-09; by Sanger method sequencing; by standard cytogenetics and fluorescence in situ hybridization (FISH) of metaphase chromosomes (Quest Diagnostics) using Abbott Molecular probes (Abbott Molecular); by microarray analysis using the Affymetrix Cytoscan HD array (Affymetrix); and by whole genome sequencing (WGS). For WGS, paired-end patient WHIM-09 fibroblast and neutrophil DNA libraries were prepared using the TruSeq DNA protocol (Illumina) and were sequenced using a HiSeq 2000 next generation sequencer (Illumina) generating $380 million reads per library of 2 3 100 bp paired-ends. Reads were mapped to build hg19 of the human genome to identify fusion junctions present in the neutrophil but not in the fibroblast samples. ground. In this way, differentially marked donor bone marrow cells could be tracked in vivo during competitive transplantation experiments. Five million bone marrow cells ($50% from each donor) were transferred via tail vein injection into recipient mice that had undergone lethal irradiation (900 rads) 8 hr prior to transplant. The mice were fed with neomycin water for 4 weeks post-irradiation. All animal experiments were performed using an NIAID Animal Care and Use Committee (ACUC) approved protocol in approved and certified facilities. For additional details, see Extended Experimental Procedures.
Transplantation Experiments
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